However, prostate cancers almost always evolve strategies to grow at low levels of androgen, and have even developed resistance to the second-generation AR antagonist enzalutamide, or the androgen biosynthesis inhibitor abiraterone acetate [29,30], a state known as castration-resistant prostate cancer (CRPC) [31]. This evidence concerns the gene AR and Familial prostate cancer.